1-Methyl-4-[3-(1,2,3,4-tetrahydro-1-naphthoyloxy)-benzoyl]piperazine.hydrochloride | 90210-20-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1-Methyl-4-[3-(1,2,3,4-tetrahydro-1-naphthoyloxy)-benzoyl]piperazine.hydrochloride
• 英文别名: [3-(4-Methylpiperazine-1-carbonyl)phenyl] 1,2,3,4-tetrahydronaphthalene-1-carboxylate;hydrochloride
• CAS: 90210-20-1
• 化学式: C₂₃H₂₆N₂O₃*ClH
• 分子量: 414.932
• InChiKey: TXGWBOJJBAZWMW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.52
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  1-methyl-4-(3-hydroxybenzoyl)piperazine 、 1,2,3,4-四氢-1-萘甲酸 以62.7%的产率得到1-Methyl-4-[3-(1,2,3,4-tetrahydro-1-naphthoyloxy)-benzoyl]piperazine.hydrochloride
  参考文献：
  名称：

  Benzoylpiperazine esters and a process for their production

  摘要：

  以下是上述化学式的中文翻译： 以下是一个苯并哌嗪酯化合物的结构式：##STR1## 其中，A代表单键或烷基、乙烯基、--O--烷基或甲基基，R.sub.1代表一个双环碳环残基，该残基可以被低烷基、低烷氧基、氧代基或硝基或卤素原子取代，或者部分饱和；一个含氧代基的芴残基；一个芴亚甲基基团；一个蒽残基；一个苯并并芘残基，该残基可以被低烷基取代，或者部分饱和；一个苯并呋喃残基或噻萘残基，该残基可以被低烷基或低烷氧基取代；一个苯并吡喃残基或苯并噻唑残基，该残基可以被氧代基或苯基取代并部分饱和；一个邻二甲酰亚胺残基；一个苯并二氮杂环残基；一个异唑啉残基，该残基可以被低烷基或苯基取代；或者一个烷基二氧基苯残基或黄色素残基；R.sub.2代表烷基、环烷基、环烷基烷基或芳基烷基，但当A是单键，R.sub.1是##STR2##，R.sub.2是甲基时，该化合物表现出优异的胰凝乳蛋白酶抑制活性。

  公开号：

  US04898876A1

文献信息

• Methods And Compositions For The Treatment Of Gastrointestinal disorders
  申请人：Currie Mark G.

  公开号：US20080025966A1

  公开（公告）日：2008-01-31

  The use of chymotrypsin inhibitors for treating various disorders, including IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), and disorders and conditions associated with constipation is described.
• Methods and Compositions for the Treatment of Hypertension and Gastrointestinal Disorders
  申请人：Talley John Jeffrey

  公开号：US20090054319A1

  公开（公告）日：2009-02-26

  The use of guanylin potentiating agents for treating various disorders, including hypertension as well as IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, chronic intestinal pseudo-obstruction, colonic pseudo-obstruction, Crohn's disease, duodenogastric reflux, dyspepsia, functional dyspepsia, nonulcer dyspepsia, a functional gastrointestinal disorder, functional heartburn, gastroesophageal reflux disease (GERD), gastroparesis, inflammatory bowel disease, irritable bowel syndrome, post-operative ileus, ulcerative colitis, chronic constipation, and disorders and conditions associated with constipation is described.
• US4898876A
  申请人：——

  公开号：US4898876A

  公开（公告）日：1990-02-06
• [EN] METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS<br/>[FR] PROCEDES ET COMPOSITIONS POUR TRAITER DES TROUBLES GASTRO-INTESTINAUX
  申请人：MICROBIA INC

  公开号：WO2005074575A2

  公开（公告）日：2005-08-18

  The use of chymotrypsin inhibitors for treating various disorders, including IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), and disorders and conditions associated with constipation is described.
• [EN] METHODS AND COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION AND GASTROINTESTINAL DISORDERS<br/>[FR] METHODES ET COMPOSITIONS POUR LE TRAITEMENT DE L'HYPERTENSION ET DE TROUBLES GASTRO-INTESTINAUX
  申请人：MICROBIA INC

  公开号：WO2006102069A2

  公开（公告）日：2006-09-28

  [EN] The use of guanylin potentiating agents for treating various disorders, including hypertension as well as IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, chronic intestinal pseudo-obstruction, colonic pseudo-obstruction, Crohn's disease, duodenogastric reflux, dyspepsia, functional dyspepsia, nonulcer dyspepsia, a functional gastrointestinal disorder, functional heartburn, gastroesophageal reflux disease (GERD), gastroparesis, inflammatory bowel disease, irritable bowel syndrome, post-operative ileus, ulcerative colitis, chronic constipation, and disorders and conditions associated with constipation is described.
  [FR] L'invention porte sur l'utilisation d'agents potentialiseurs pour traiter différents troubles dont le syndrome du côlon irritable et d'autres troubles et états gastro-intestinaux tels que: les troubles de la motilité gastro-intestinale, la pseudo obstruction intestinale, la pseudo obstruction du côlon, la maladie de Crohn, le reflux duodénogastrique, la dyspepsie, la dyspepsie fonctionnelle, la dyspepsie non ulcéreuse, les troubles gastro-intestinaux fonctionnels, la pyrosis fonctionnelle, le reflux gastrooesophagien, la gastroparésie, l'inflammation de l'intestin, le syndrome de l'intestin irritable, l'occlusion intestinale post opératoire, la rectocolite hémorragique, la constipation chronique, et des troubles et états associés à la constipation.